Healthcare: Industry Trends Q4 2024

In this in-depth trends Analysis of the Healthcare Industry for Q4 2024, we cover:

1.    Economic Stabilization and Cost Management Challenges
2.    AI-powered Drug Discovery, Digital Transformation and Regulatory Oversight
3.    Mergers & Acquisitions: Weight-Loss Treatments and Digital Health Solutions
4.    Workforce Challenges and Retention Strategies
5.    Patient Experience and Virtual Health Expansion
6.    Precision Diagnostics Rebounds While HealthTech Slows Down
7.    Medical Devices: A Shift Towards Acute Care and rising interest in 3D bioprinting
8.    Venture Investment Consolidation in Biopharma and Medtech
9.    M&A Surges in Medtech and Slowdown in Biopharma
10.    IPO Market Recovery in Medtech and Biopharma
11.    Licensing and R&D Partnerships Move Towards Conservative Structures
12.    Expanding Markets in Urology, Enteral Feeding, and Orthopaedic Implants

1. Economic Stabilization and Cost Management Challenges

The healthcare sector in Q4 2024 has shown signs of stabilization after years of economic turbulence. However, cost pressures remain a significant concern, with healthcare costs expected to rise between 7–9% in 2025, the highest in over a decade. This surge is driven by inflation, increased labor and supply expenses, and the rising demand for expensive drugs.

Health systems continue to focus on cost containment strategies, including shifting care to lower-cost ambulatory settings, with outpatient volumes projected to grow by 18–21% over the next decade.

2. AI-powered Drug Discovery, Digital Transformation and Regulatory Oversight

AI and digital transformation continue to reshape healthcare, with over 70% of global health system executives prioritizing operational efficiency.

Generative AI, robotics, and cognitive automation are currently leveraged to reduce provider burnout and streamline workflows.

The adoption of AI-powered drug discovery has tripled, with $5.6 billion invested in biotech AI in 2024.

AI-designed drugs that entered clinical trials in 2020 are expected to report results in 2025, marking a crucial year for AI validation in biopharma.

Despite AI’s promise, regulatory challenges persist. The EU AI Act has introduced strict oversight, categorizing AI applications into risk levels and prohibiting high-risk uses.

In the U.S., regulatory bodies are also tightening compliance requirements, creating hurdles for AI deployment in healthcare.

3. Mergers & Acquisitions: Weight-Loss Treatments, ASCs and Digital Health Solutions

The healthcare M&A market remained resilient in Q4 2024, with continued momentum despite economic uncertainty.

Demand for innovative therapies and improved financing conditions have driven acquisitions, particularly in weight-loss treatments and digital health solutions.

Alternative funding models, such as physician-backed ambulatory surgical centers (ASCs) and private equity ownership, are gaining traction, further driving consolidation.

Looking ahead to 2025, strategic M&A activity is expected to intensify, focusing on AI-driven developments and personalized therapies.

4. Workforce Challenges and Retention Strategies

A persistent global healthcare workforce shortage remains a critical issue. The WHO projects a 10-million-worker deficit by 2030.

In 2024, widespread strikes in South Korea, the UK, and New Zealand highlighted demands for better pay and improved working conditions for healthcare professionals.

To combat burnout, health systems are investing in workflow optimization and digital tools, which could free up 13–21% of nurses’ time annually. Additionally, 67% of healthcare executives are prioritizing mental health initiatives to enhance workforce retention.

5. Patient Experience and Early Disease Detection

Patient expectations are evolving as they gain greater access to health data and digital tools.

Seventy-two percent of executives are prioritizing consumer experience, with AI-powered predictive analytics improving early disease detection.

Virtual health remains a key component of accessibility, with 65% of U.S. patients preferring virtual visits. However, financial viability remains a challenge. Some health systems are scaling back virtual care due to cost pressures, highlighting the need for careful ROI analysis.

6. Precision Diagnostics Rebounds While HealthTech Slows Down

Biopharma AI dominated investment activity in 2024, with significant funds flowing into AI-powered drug discovery and protein engineering. While overall investment dollars have declined from peak levels, 2024 saw more deals than in 2021, indicating a shift toward quality over quantity.

Early-stage investments continue to surge, with nearly 40% of all healthcare deals occurring at the seed stage.

HealthTech, however, has seen slower growth. While companies with proven track records continue to attract investment, new startups must demonstrate tangible value quickly to secure funding. Meanwhile, the diagnostics/tools sector is rebounding, particularly in precision diagnostics and liquid biopsy, driven by the increasing role of AI in aggregating healthcare data.

7. Medical Devices: A Shift Towards Acute Care and rising interest in 3D bioprinting

The medical device sector has faced challenges, with exits remaining low. However, hospitals are emerging as a key driver for device innovation, with new imaging and monitoring technologies gaining traction.

IPO activity in the device sector is expected to pick up in 2025, particularly in acute care-focused startups.

The medical device contract manufacturing market is projected to expand at an 11.4% CAGR from 2024 to 2031.

Advanced Manufacturing with 3D printing

Outsourcing trends in healthcare, combined with advancements in manufacturing technologies like 3D printing and automation, are driving this growth. The increasing demand for novel medical devices is further fuelling contract manufacturing as companies seek cost-effective and scalable production solutions.

The adoption of 3D printing in medical device production is accelerating, with the market expected to grow at a 17.1% CAGR through 2031.

Emerging Technology: Personalized healthcare solutions, biofabrication techniques, and Laser Beam Melting technology are key drivers.

Rising Interest in 3D bioprinting

The rising interest in functional living tissue printing (3D bioprinting) could further transform the industry, pushing companies towards more customized and patient-specific device development.

8. Venture Investment Consolidation in Biopharma and Medtech

Venture investment in biopharma and MedTech remained strong in 2024 despite fewer rounds.

Biopharma secured $26 billion across 416 rounds, while MedTech raised $19.1 billion through 691 rounds.

A key trend was the concentration of capital into larger rounds, with MedTech seeing 42 rounds above $100 million and 79 rounds exceeding $50 million. Similarly, biopharma had 98 rounds surpassing $100 million, with notable deals such as Kailera Therapeutics’ $400 million Series A and Seaport Therapeutics’ $225 million Series B. The shift towards fewer but larger investments indicates investor confidence in high-value opportunities while maintaining a selective approach.

9. M&A Surges in Medtech and Slowdown in Biopharma

Medtech M&A surged in 2024, with 305 transactions totaling $63.1 billion, compared to 134 deals in 2023. This was driven by major acquisitions, including J&J’s $13.1 billion purchase of Shockwave and Novo Holdings’ $16.5 billion acquisition of Catalent.

In contrast, biopharma saw only 18 M&A deals in Q4 2024, totaling $5.9 billion—the lowest since early 2022. The disparity highlights a shift in deal-making strategies, with medtech companies consolidating aggressively while biopharma M&A remains cautious despite higher median deal values.

10. IPO Market Recovery in Medtech and Biopharma

The IPO market showed signs of revival in both sectors.

Medtech saw four IPOs in 2024, raising $744.5 million, while biopharma had 19 IPOs, generating $3.8 billion.

Notable biopharma IPOs in Q4 included Septerna ($331 million), Upstream Bio ($293 million), and CAMP4 ($75 million). The cautious but steady recovery suggests growing investor interest, though valuations and overall deal volume remain lower than pre-2022 levels.

11. Licensing and R&D Partnerships Move Towards Conservative Structures

Both MedTech and biopharma experienced a shift towards more conservative licensing deals. Medtech recorded 1,051 licensing deals worth $7.2 billion, with $597 million in upfront payments, while biopharma licensing reached a total value of $171.2 billion.

Upfront payments in biopharma stabilized at 7% of deal value, halting the previous downward trend. Notably, 30 biopharma deals in 2024 had upfront payments exceeding $100 million. This trend indicates a focus on de-risking transactions, with companies securing smaller upfront payments while retaining longer-term upside potential.

12. Expanding Markets in Urology, Enteral Feeding, and Orthopaedic Implants

The urology devices market is set to reach $61.62 billion by 2031, driven by an aging population and rising urological disorders. Similarly, the enteral feeding devices market is projected to grow at a 6.1% CAGR, fueled by increasing chronic disease prevalence and home healthcare expansion. Meanwhile, orthopedic implants remain in high demand, with the market expected to reach $32.92 billion by 2031, reflecting a broader shift towards precision medicine and patient-specific solutions.

Final Take

The healthcare industry in Q4 2024 is navigating economic pressures, digital transformation, workforce challenges, and evolving investment landscapes.

While M&A activity in medtech is accelerating, biopharma remains cautious.

AI and automation are enhancing patient care and operational efficiency, but regulatory hurdles persist.
Investors are favoring larger, high-value opportunities while medical devices and precision diagnostics continue to grow. As the industry adapts to these shifts, healthcare stakeholders must balance innovation with financial sustainability to drive long-term growth.

References